{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:29Z","timestamp":1740106949082,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"China National Major Project for New Drug Innovation","award":["2017ZX09304015"],"award-info":[{"award-number":["2017ZX09304015"]}]},{"name":"Scientific Research Foundation of Fujian Cancer Hospital","award":["2021YNY02"],"award-info":[{"award-number":["2021YNY02"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J05241"],"award-info":[{"award-number":["2023J05241"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010031","name":"Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2023M734015"],"award-info":[{"award-number":["2023M734015"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00277-023-05491-0","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T05:02:02Z","timestamp":1697778122000},"page":"211-226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study"],"prefix":"10.1007","volume":"103","author":[{"given":"Qiaofeng","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haizhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanben","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-4964","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"key":"5491_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"L Teras","year":"2016","unstructured":"Teras L et al (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA: Cancer J Clin 66:443\u2013459. https:\/\/doi.org\/10.3322\/caac.21357","journal-title":"CA: Cancer J Clin"},{"key":"5491_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386:351\u2013363. https:\/\/doi.org\/10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"},{"key":"5491_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"J Friedberg","year":"2011","unstructured":"Friedberg J (2011) Relapsed\/refractory diffuse large B-cell lymphoma. Hematology 2011:498\u2013505. https:\/\/doi.org\/10.1182\/asheducation-2011.1.498","journal-title":"Hematology"},{"key":"5491_CR4","doi-asserted-by":"publisher","unstructured":"(1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Eng J Med 329:987\u2013994. https:\/\/doi.org\/10.1056\/nejm199309303291402","DOI":"10.1056\/nejm199309303291402"},{"key":"5491_CR5","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"L Sehn","year":"2007","unstructured":"Sehn L et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857\u20131861. https:\/\/doi.org\/10.1182\/blood-2006-08-038257","journal-title":"Blood"},{"key":"5491_CR6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z et al (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123:837\u2013842. https:\/\/doi.org\/10.1182\/blood-2013-09-524108","journal-title":"Blood"},{"key":"5491_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"A Alizadeh","year":"2000","unstructured":"Alizadeh A et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503\u2013511. https:\/\/doi.org\/10.1038\/35000501","journal-title":"Nature"},{"key":"5491_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679\u2013690. https:\/\/doi.org\/10.1038\/s41591-018-0016-8","journal-title":"Nat Med"},{"key":"5491_CR9","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.1182\/blood-2008-02-136374","volume":"111","author":"R Malumbres","year":"2008","unstructured":"Malumbres R et al (2008) Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 111:5509\u20135514. https:\/\/doi.org\/10.1182\/blood-2008-02-136374","journal-title":"Blood"},{"key":"5491_CR10","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/blood-2011-03-345272","volume":"118","author":"A Alizadeh","year":"2011","unstructured":"Alizadeh A et al (2011) Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 118:1350\u20131358. https:\/\/doi.org\/10.1182\/blood-2011-03-345272","journal-title":"Blood"},{"key":"5491_CR11","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R et al (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378:1396\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa1801445","journal-title":"N Engl J Med"},{"key":"5491_CR12","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1056\/NEJMoa032520","volume":"350","author":"I Lossos","year":"2004","unstructured":"Lossos I et al (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828\u20131837. https:\/\/doi.org\/10.1056\/NEJMoa032520","journal-title":"N Engl J Med"},{"key":"5491_CR13","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2021.0193","author":"Y Qin","year":"2021","unstructured":"Qin Y et al (2021) BCL2Prognostic value of and genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP. Cancer Biol Med. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2021.0193","journal-title":"Cancer Biol Med"},{"key":"5491_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.13420","volume":"170","author":"H Adams","year":"2015","unstructured":"Adams H, Nievelstein R, Kwee T (2015) Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. Br J Haematol 170:185\u2013191. https:\/\/doi.org\/10.1111\/bjh.13420","journal-title":"Br J Haematol"},{"key":"5491_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"G Wright","year":"2020","unstructured":"Wright G et al (2020) A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37:551-568.e514. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.015","journal-title":"Cancer Cell"},{"key":"5491_CR16","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1200\/jco.2014.60.2383","volume":"33","author":"D Scott","year":"2015","unstructured":"Scott D et al (2015) Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol 33:2848\u20132856. https:\/\/doi.org\/10.1200\/jco.2014.60.2383","journal-title":"J Clin Oncol"},{"key":"5491_CR17","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/jco.2011.41.0985","volume":"30","author":"N Johnson","year":"2012","unstructured":"Johnson N et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3452\u20133459. https:\/\/doi.org\/10.1200\/jco.2011.41.0985","journal-title":"J Clin Oncol"},{"key":"5491_CR18","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/leu.2011.112","volume":"25","author":"R Wilcox","year":"2011","unstructured":"Wilcox R et al (2011) The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 25:1502\u20131509. https:\/\/doi.org\/10.1038\/leu.2011.112","journal-title":"Leukemia"},{"key":"5491_CR19","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjh.16263","volume":"188","author":"L Bento","year":"2020","unstructured":"Bento L et al (2020) New prognosis score including absolute lymphocyte\/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). Br J Haematol 188:888\u2013897. https:\/\/doi.org\/10.1111\/bjh.16263","journal-title":"Br J Haematol"},{"key":"5491_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1634\/theoncologist.2019-0756","volume":"25","author":"C Cheng","year":"2020","unstructured":"Cheng C et al (2020) Hepatitis B surface antigen positivity is an independent unfavorable prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Oncologist 25:793\u2013802. https:\/\/doi.org\/10.1634\/theoncologist.2019-0756","journal-title":"Oncologist"},{"key":"5491_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s12185-020-02818-9","volume":"111","author":"Y Wei","year":"2020","unstructured":"Wei Y et al (2020) Albumin improves stratification in the low IPI risk patients with diffuse large B-cell lymphoma. Int J Hematol 111:681\u2013685. https:\/\/doi.org\/10.1007\/s12185-020-02818-9","journal-title":"Int J Hematol"},{"key":"5491_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12935-020-01535-x","volume":"20","author":"C Luan","year":"2020","unstructured":"Luan C, Wang F, Wei N, Chen B (2020) Prognostic nutritional index and the prognosis of diffuse large b-cell lymphoma: a meta-analysis. Cancer Cell Int 20:455. https:\/\/doi.org\/10.1186\/s12935-020-01535-x","journal-title":"Cancer Cell Int"},{"key":"5491_CR23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41416-021-01434-6","volume":"125","author":"J Cai","year":"2021","unstructured":"Cai J et al (2021) A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study. Br J Cancer 125:402\u2013412. https:\/\/doi.org\/10.1038\/s41416-021-01434-6","journal-title":"Br J Cancer"},{"key":"5491_CR24","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3389\/fonc.2020.01093","volume":"10","author":"J Wang","year":"2020","unstructured":"Wang J, Zhou M, Zhou R, Xu J, Chen B (2020) Nomogram for predicting the overall survival of adult patients with primary gastrointestinal diffuse large B cell lymphoma: a SEER-based study. Front Oncol 10:1093. https:\/\/doi.org\/10.3389\/fonc.2020.01093","journal-title":"Front Oncol"},{"key":"5491_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.blre.2018.03.005","volume":"32","author":"J Wight","year":"2018","unstructured":"Wight J, Chong G, Grigg A, Hawkes E (2018) Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. Blood Rev 32:400\u2013415. https:\/\/doi.org\/10.1016\/j.blre.2018.03.005","journal-title":"Blood Rev"},{"key":"5491_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cncr.21586","volume":"106","author":"G Wu","year":"2006","unstructured":"Wu G, Keating A (2006) Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma. Cancer 106:247\u2013257. https:\/\/doi.org\/10.1002\/cncr.21586","journal-title":"Cancer"},{"key":"5491_CR27","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1002\/cncr.24352","volume":"115","author":"K Touijer","year":"2009","unstructured":"Touijer K, Scardino P (2009) Nomograms for staging, prognosis, and predicting treatment outcomes. Cancer 115:3107\u20133111. https:\/\/doi.org\/10.1002\/cncr.24352","journal-title":"Cancer"},{"key":"5491_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/sj.leu.2404449","volume":"21","author":"P De Paepe","year":"2007","unstructured":"De Paepe P, De Wolf-Peeters C (2007) Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 21:37\u201343. https:\/\/doi.org\/10.1038\/sj.leu.2404449","journal-title":"Leukemia"},{"key":"5491_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/blood-2012-08-450106","volume":"121","author":"F Hong","year":"2013","unstructured":"Hong F, Kahl B, Gray R (2013) Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma. Blood 121:156\u2013158. https:\/\/doi.org\/10.1182\/blood-2012-08-450106","journal-title":"Blood"},{"key":"5491_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.10.006","volume":"133","author":"J Jelicic","year":"2019","unstructured":"Jelicic J, Larsen T, Maksimovic M, Trajkovic G (2019) Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review. Crit Rev Oncol Hematol 133:1\u201316. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.10.006","journal-title":"Crit Rev Oncol Hematol"},{"key":"5491_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/oxfordjournals.annonc.a058324","volume":"3","author":"J Rodr\u00edguez","year":"1992","unstructured":"Rodr\u00edguez J et al (1992) A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the \u2018tumor score\u2019. Ann Oncol 3:711\u2013717. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a058324","journal-title":"Ann Oncol"},{"key":"5491_CR32","first-page":"5372","volume":"46","author":"L Danieu","year":"1986","unstructured":"Danieu L, Wong G, Koziner B, Clarkson B (1986) Predictive model for prognosis in advanced diffuse histiocytic lymphoma. Can Res 46:5372\u20135379","journal-title":"Can Res"},{"key":"5491_CR33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1200\/jco.1991.9.2.220","volume":"9","author":"P Hoskins","year":"1991","unstructured":"Hoskins P, Ng V, Spinelli J, Klimo P, Connors J (1991) Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 9:220\u2013226. https:\/\/doi.org\/10.1200\/jco.1991.9.2.220","journal-title":"J Clin Oncol"},{"key":"5491_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/annonc\/mdj030","volume":"17","author":"K Savage","year":"2006","unstructured":"Savage K et al (2006) Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 17:123\u2013130. https:\/\/doi.org\/10.1093\/annonc\/mdj030","journal-title":"Ann Oncol"},{"key":"5491_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1751-553X.2007.00900.x","volume":"30","author":"N Tomita","year":"2008","unstructured":"Tomita N et al (2008) Adjuvant radiotherapy to an initial bulky mass in diffuse large B-cell lymphoma: lack of survival benefit. Int J Lab Hematol 30:53\u201357. https:\/\/doi.org\/10.1111\/j.1751-553X.2007.00900.x","journal-title":"Int J Lab Hematol"},{"key":"5491_CR36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/s1470-2045(08)70078-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M et al (2008) Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 9:435\u2013444. https:\/\/doi.org\/10.1016\/s1470-2045(08)70078-0","journal-title":"Lancet Oncol"},{"key":"5491_CR37","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/jco.2005.05.1003","volume":"24","author":"T Habermann","year":"2006","unstructured":"Habermann T et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121\u20133127. https:\/\/doi.org\/10.1200\/jco.2005.05.1003","journal-title":"J Clin Oncol"},{"key":"5491_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"key":"5491_CR39","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s12288-014-0479-9","volume":"31","author":"H Takasaki","year":"2015","unstructured":"Takasaki H et al (2015) Post-treatment PET-CT Findings may predict the prognosis of DLBCL with a bulky mass. Indian J Hematol Blood Transfus 31:346\u2013351. https:\/\/doi.org\/10.1007\/s12288-014-0479-9","journal-title":"Indian J Hematol Blood Transfus"},{"key":"5491_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/s1470-2045(08)70111-6","volume":"9","author":"J Ribera","year":"2008","unstructured":"Ribera J (2008) Adverse prognosis of bulky disease in good-risk DLBCL. Lancet Oncol 9:406\u2013407. https:\/\/doi.org\/10.1016\/s1470-2045(08)70111-6","journal-title":"Lancet Oncol"},{"key":"5491_CR41","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/cam4.2798","volume":"9","author":"S Tokola","year":"2020","unstructured":"Tokola S, Kuitunen H, Turpeenniemi-Hujanen T, Kuittinen O (2020) Significance of bulky mass and residual tumor-treated with or without consolidative radiotherapy-To the risk of relapse in DLBCL patients. Cancer Med 9:1966\u20131977. https:\/\/doi.org\/10.1002\/cam4.2798","journal-title":"Cancer Med"},{"key":"5491_CR42","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ejh.13364","volume":"104","author":"A Gutierrez","year":"2020","unstructured":"Gutierrez A et al (2020) Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol 104:400\u2013408. https:\/\/doi.org\/10.1111\/ejh.13364","journal-title":"Eur J Haematol"},{"key":"5491_CR43","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1093\/annonc\/mdp531","volume":"21","author":"A Bari","year":"2010","unstructured":"Bari A et al (2010) Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 21:1486\u20131491. https:\/\/doi.org\/10.1093\/annonc\/mdp531","journal-title":"Ann Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05491-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05491-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05491-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T18:04:11Z","timestamp":1704218651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05491-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["5491"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05491-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Cancer Hospital, Chinese Academy of Medical Sciences (No. NCC2018JJJ-004) and Fujian Cancer Hospital (No. SQ2022-090\u201301).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was waived due to the retrospective nature of the present study, and data of the participants have been anonymized.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}